NYSE:MRK - Merck & Co., Inc. Stock Price, Price Target & More

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc. declared a quarterly dividend on Tuesday, May 22nd. Shareholders of record on Friday, June 15th will be paid a dividend of $0.48 per share on Monday, July 9th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.15%. The ex-dividend date is Thursday, June 14th. View Merck & Co., Inc.'s Dividend History.

Merck & Co., Inc. declared that its board has approved a stock buyback program on Saturday, December 2nd 2017, which authorizes the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board of directors believes its stock is undervalued.

Merck & Co., Inc. (NYSE:MRK) announced its quarterly earnings results on Tuesday, May, 1st. The company reported $1.05 earnings per share for the quarter, beating analysts' consensus estimates of $1.00 by $0.05. The firm earned $10.04 billion during the quarter, compared to the consensus estimate of $10.09 billion. Merck & Co., Inc. had a net margin of 4.31% and a return on equity of 30.93%. The business's quarterly revenue was up 6.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.88 EPS. View Merck & Co., Inc.'s Earnings History.

Merck & Co., Inc. is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for Merck & Co., Inc..

Merck & Co., Inc. issued an update on its FY18 earnings guidance on Tuesday, May, 1st. The company provided EPS guidance of $4.16-4.28 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.19. The company issued revenue guidance of $41.8-43.0 billion, compared to the consensus revenue estimate of $41.86 billion.

18 brokers have issued 1 year price objectives for Merck & Co., Inc.'s stock. Their predictions range from $56.00 to $72.00. On average, they anticipate Merck & Co., Inc.'s stock price to reach $65.8644 in the next year. View Analyst Ratings for Merck & Co., Inc..

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Allergan (AGN), Celgene (CELG) and Shire (SHPG).

News headlines about MRK stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Merck & Co., Inc. earned a daily sentiment score of 0.10 on Accern's scale. They also gave media stories about the company an impact score of 44.98 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Merck & Co., Inc.'s stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.85%), Franklin Resources Inc. (1.82%), Northern Trust Corp (1.24%), Boston Partners (0.55%), Legal & General Group Plc (0.50%) and Barrow Hanley Mewhinney & Strauss LLC (0.47%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, C Robert Kidder, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Federated Investors Inc. PA, Northern Trust Corp, Boston Partners, Barrow Hanley Mewhinney & Strauss LLC, Swiss National Bank, Independent Franchise Partners LLP and Legal & General Group Plc. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Julie L Gerberding, Michael J Holston, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co., Inc..

MRK stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Pzena Investment Management LLC, Natixis, Manning & Napier Group LLC, Levin Capital Strategies L.P., American Century Companies Inc., Sound Shore Management Inc. CT and Summit Trail Advisors LLC. View Insider Buying and Selling for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $60.99.

Merck & Co., Inc. has a market capitalization of $167.24 billion and generates $40.12 billion in revenue each year. The company earns $2.39 billion in net income (profit) each year or $3.98 on an earnings per share basis. Merck & Co., Inc. employs 69,000 workers across the globe.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]